Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia

Multiple Cancer Types

This first-in-human (FIH) dose-escalation and dose-validation / expansion study will assess KO-539, a menin-MLL(KMT2A) inhibitor, in patients with refractory or relapsed acute myeloid leukemia (AML).
Leukemia, Phase I
I/II
Strickland, Stephen
NCT04067336
VICCHEMP20122

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: